Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5867 Articles

cgblaine22 | Apr 26, 2014 at 8:30 AM EDT

Biotech: The Poster Child for Market Volatility in 2014

The NYSE Arca Biotechnology Index fell nearly 9% between a peak on Jan. 22 and a low on Feb. 5.…

Trey Thoelcke | Apr 24, 2014 at 7:00 AM EDT

Expired Patents Take a Bite out of Eli Lilly Results

Eli Lilly reported disappointing first-quarter 2014 results before markets opened Thursday, due in part to the impact of U.S. patent…

Jon C. Ogg | Apr 23, 2014 at 3:35 PM EDT

Why Investors Are Not Chasing Gilead Endlessly Higher

ThinkstockBy any stretch of normal measurement in earnings season, Gilead Sciences Inc. (NASDAQ: GILD) should have been a rocketing stock…

Jon C. Ogg | Apr 23, 2014 at 1:35 PM EDT

Lombard Signals More Evidence of IPO Market Reality Check

The market for initial public offerings was getting to be a bit ridiculous. Now that volatility has returned in the…

Jon C. Ogg | Apr 23, 2014 at 10:50 AM EDT

Companies Betting on the Next 10 Blockbuster Drugs

24/7 Wall St. wanted to evaluate the prospects for several would-be blockbuster drugs. Some of these have approvals already in…

Jon C. Ogg | Apr 23, 2014 at 8:50 AM EDT

UBS Top Stocks to Buy Working for Cancer Cures

In a new research report, the Healthcare team at UBS took an in-depth look at the top companies that are…

Jon C. Ogg | Apr 22, 2014 at 4:48 PM EDT

An Earnings Tale of Two Biotechs: Gilead vs. Amgen

ThinkstockGilead Sciences Inc. (NASDAQ: GILD) and Amgen Inc. (NASDAQ: AMGN) have both reported earnings. This is a definite difference in…

Jon C. Ogg | Apr 22, 2014 at 12:00 PM EDT

Biotech Earnings Previews: Amgen, Biogen Idec, Gilead, Celgene

ThinkstockBiotech stocks took it on the chin during the sell-off. In fact, biotech stocks may have even led the sell-off…

Jon C. Ogg | Apr 22, 2014 at 10:40 AM EDT

GW Pharma Dual Cannabinoid Endorsement: Morgan Stanley and Jim Cramer

GW Pharmaceuticals is far from your typical pharma or biotech stock. It is also far from your typical legalized marijuana…

Trey Thoelcke | Apr 22, 2014 at 9:50 AM EDT

Jefferies Initiates Coverage on Specialty Pharmaceutical Takeover Candidates

The specialty pharmaceutical sector is exploding with news of takeovers, exchanges and possible mergers. Here are some of the top…

Jon C. Ogg | Apr 21, 2014 at 1:25 PM EDT

What a Combined Pfizer and AstraZeneca Would Look Like, and Face

ThinkstockIt is not that common that you hear about mergers in the $50 billion range. But what about when you…

Paul Ausick | Apr 21, 2014 at 10:10 AM EDT

Odds of Sarepta Drug Approval Rise Sharply

Shares of Sarepta Therapeutics went through the roof Monday morning following an announcement that it plans to have a New…

Trey Thoelcke | Apr 21, 2014 at 9:05 AM EDT

J.P. Morgan’s Top Biotech and Health Care Picks With Huge Upside

In a new research report, the J.P. Morgan health care team highlights their top names to buy after the sell-off…

Paul Ausick | Apr 18, 2014 at 8:20 AM EDT

Obamacare Sign-Ups Top 8 Million

ThinkstockAt a press conference on Thursday afternoon, President Obama announced that the number of Americans using the public exchanges to…

Trey Thoelcke | Apr 17, 2014 at 7:30 AM EDT

UnitedHealth Group Revenues Stung by Obamacare

UnitedHealth Group reported better-than-expected first-quarter earnings before markets opened Thursday, but revenues fell short of consensus estimates.

1 … 288 289 290 291 292 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Biotech: The Poster Child for Market Volatility in 2014

Expired Patents Take a Bite out of Eli Lilly Results

Why Investors Are Not Chasing Gilead Endlessly Higher

Lombard Signals More Evidence of IPO Market Reality Check

Companies Betting on the Next 10 Blockbuster Drugs

UBS Top Stocks to Buy Working for Cancer Cures

An Earnings Tale of Two Biotechs: Gilead vs. Amgen

Biotech Earnings Previews: Amgen, Biogen Idec, Gilead, Celgene

GW Pharma Dual Cannabinoid Endorsement: Morgan Stanley and Jim Cramer

Jefferies Initiates Coverage on Specialty Pharmaceutical Takeover Candidates

What a Combined Pfizer and AstraZeneca Would Look Like, and Face

Odds of Sarepta Drug Approval Rise Sharply

J.P. Morgan’s Top Biotech and Health Care Picks With Huge Upside

Obamacare Sign-Ups Top 8 Million

UnitedHealth Group Revenues Stung by Obamacare

Washington Just Committed $17.5 Billion to New Reactors. Uranium Funds Missed the Memo

She Returned to a Classroom at 64. Her Wages Earned No Social Security Credit, but Every Dollar Counted Against Her.

His Military Pension Didn’t Shrink His Social Security. His New Defense-Plant Paycheck Could.

She Returned to a Classroom at 64. Her Wages Earned No Social Security Credit, but Every Dollar Counted Against Her.

His Military Pension Didn't Shrink His Social Security. His New Defense-Plant Paycheck Could.

Washington Just Committed $17.5 Billion to New Reactors. Uranium Funds Missed the Memo

She Returned to a Classroom at 64. Her Wages Earned No Social Security Credit, but Every Dollar Counted Against Her.

Health and Healthcare Articles

All Health and Healthcare Articles

Biotech: The Poster Child for Market Volatility in 2014

Expired Patents Take a Bite out of Eli Lilly Results

Why Investors Are Not Chasing Gilead Endlessly Higher

Lombard Signals More Evidence of IPO Market Reality Check

Companies Betting on the Next 10 Blockbuster Drugs

UBS Top Stocks to Buy Working for Cancer Cures

An Earnings Tale of Two Biotechs: Gilead vs. Amgen

Biotech Earnings Previews: Amgen, Biogen Idec, Gilead, Celgene

GW Pharma Dual Cannabinoid Endorsement: Morgan Stanley and Jim Cramer

Jefferies Initiates Coverage on Specialty Pharmaceutical Takeover Candidates

What a Combined Pfizer and AstraZeneca Would Look Like, and Face

Odds of Sarepta Drug Approval Rise Sharply

J.P. Morgan’s Top Biotech and Health Care Picks With Huge Upside

Obamacare Sign-Ups Top 8 Million

UnitedHealth Group Revenues Stung by Obamacare

Washington Just Committed $17.5 Billion to New Reactors. Uranium Funds Missed the Memo

She Returned to a Classroom at 64. Her Wages Earned No Social Security Credit, but Every Dollar Counted Against Her.

His Military Pension Didn’t Shrink His Social Security. His New Defense-Plant Paycheck Could.

Featured Reads

She Returned to a Classroom at 64. Her Wages Earned No Social Security Credit, but Every Dollar Counted Against Her.

His Military Pension Didn't Shrink His Social Security. His New Defense-Plant Paycheck Could.